Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season

Respiratory syncytial virus (RSV) causes most of the cases of bronchiolitis and thousands of deaths annually, particularly in infants less than 6 months old. In Catalonia (Spain), infants born between April 2023 and March 2024 aged 0–6 months during their first RSV season have been candidates to rec...

Descripción completa

Detalles Bibliográficos
Autores: Perramon Malavez, Aida, López de Rioja, Víctor, Coma, Ermengol, Hermosilla Pérez, Eduardo, Fina, Francesc, Martínez Marcos, Montserrat, Mendioroz, Jacobo, Cabezas, Carmen, Montañola-Sales, Cristina, Prats, Clara, Soriano-Arandes, Antoni
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Ramon Llull (URL)
Repositorio:DAU Arxiu Digital de la Universitat Ramon Llull
OAI Identifier:oai:dau.url.edu:20.500.14342/4730
Acceso en línea:http://hdl.handle.net/20.500.14342/4730
https://doi.org/10.1007/s00431-024-05779-x
Access Level:acceso abierto
Palabra clave:Nirsevimab
RSV
Respiratory syncytial virus
Bronchiolitis
Epidemiology
Infants
Bronquitis en els infants
616.2
id ES_bc1d0ec92e2e8bc07e22b2f3513046b3
oai_identifier_str oai:dau.url.edu:20.500.14342/4730
network_acronym_str ES
network_name_str España
repository_id_str
spelling Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 seasonPerramon Malavez, AidaLópez de Rioja, VíctorComa, ErmengolHermosilla Pérez, EduardoFina, FrancescMartínez Marcos, MontserratMendioroz, JacoboCabezas, CarmenMontañola-Sales, CristinaPrats, ClaraSoriano-Arandes, AntoniNirsevimabRSVRespiratory syncytial virusBronchiolitisEpidemiologyInfantsBronquitis en els infants616.2Respiratory syncytial virus (RSV) causes most of the cases of bronchiolitis and thousands of deaths annually, particularly in infants less than 6 months old. In Catalonia (Spain), infants born between April 2023 and March 2024 aged 0–6 months during their first RSV season have been candidates to receive nirsevimab, the novel monoclonal antibody against RSV, since October 2023. We aimed to analyse the dynamics of all-causes bronchiolitis diagnoses and RSV community infections in the current season and compare them to pre-nirsevimab epidemics. We collected epidemiological data from the Information System for Surveillance of Infections in Catalonia (SIVIC) on daily all-causes bronchiolitis clinical diagnoses and RSV-confirmed cases provided by rapid antigen tests in primary care practices. We calculated the rate ratio (RR) for the incidence of all-causes bronchiolitis for children aged 0-11 m-old with respect to 12-35 m-old between September 2014 and January 2024. We analysed the RR of the incidence of RSV-confirmed infection for 0-11 m-old and 12-35 m-old with respect to the > 35 m-old, from January 2021 to January 2024. We then computed the relative difference of the RR, designated as percentage of reduction of risk, between season 2023/2024 and former epidemics. With a global coverage recorded rate for nirsevimab of 82.2% in January 2024, the age-specific 0-11 m-old RR (95% CI) of RSV infection incidence for > 35 m-old was 1.7 (1.5–2.0) in season 2023/2024. The RR (95% CI) had been 7.4 (5.6–9.9), 8.8 (6.9–11.3), and 7.1 (5.7–8.9) in 2020/2021, 2021/2022, and 2022/2023, respectively. Regarding the incidence of all-causes bronchiolitis for the 0-11 m-old group compared to the 12-35 m-old, the pre-pandemic (2014/2015–2019/2020) and 2022/2023 RR (95% CI) were 9.4 (9.2–9.6) and 6.0 (5.7–6.2), respectively, significantly higher than the RR of 3.6 (3.4–3.8) for the most recent season, 2023/2024. Conclusion: Concurring with the introduction of nirsevimab, the risk of RSV infection for infants aged 0-11 m-old compared to > 35 m-old has been reduced by 75.6% (73.4–77.5) in last season, and the risk for all-causes bronchiolitis for 12-35 m-old by 61.9% (60.9–62.9) from the pre-pandemic period and by 39.8% (39.3–40.2) from the 2022/2023 epidemic, despite high RSV community transmission, especially in older infants.info:eu-repo/semantics/publishedVersionSpringerUniversitat Ramon Llull. IQS202520252024info:eu-repo/semantics/article9 p.application/pdfhttp://hdl.handle.net/20.500.14342/4730https://doi.org/10.1007/s00431-024-05779-xreponame:DAU Arxiu Digital de la Universitat Ramon Llullinstname:Universitat Ramon Llull (URL)InglésEuropean Journal of Pediatrics. 2024;183:5181–5189info:eu-repo/grantAgreement/Fundació La Marató TV3/202134–30-31/info:eu-repo/grantAgreement/AEI-MCIN/PN I+D/PDI2022-139215NB-I00© L'autor/aAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:dau.url.edu:20.500.14342/47302026-06-21T06:40:37Z
dc.title.none.fl_str_mv Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
title Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
spellingShingle Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
Perramon Malavez, Aida
Nirsevimab
RSV
Respiratory syncytial virus
Bronchiolitis
Epidemiology
Infants
Bronquitis en els infants
616.2
title_short Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
title_full Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
title_fullStr Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
title_full_unstemmed Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
title_sort Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
dc.creator.none.fl_str_mv Perramon Malavez, Aida
López de Rioja, Víctor
Coma, Ermengol
Hermosilla Pérez, Eduardo
Fina, Francesc
Martínez Marcos, Montserrat
Mendioroz, Jacobo
Cabezas, Carmen
Montañola-Sales, Cristina
Prats, Clara
Soriano-Arandes, Antoni
author Perramon Malavez, Aida
author_facet Perramon Malavez, Aida
López de Rioja, Víctor
Coma, Ermengol
Hermosilla Pérez, Eduardo
Fina, Francesc
Martínez Marcos, Montserrat
Mendioroz, Jacobo
Cabezas, Carmen
Montañola-Sales, Cristina
Prats, Clara
Soriano-Arandes, Antoni
author_role author
author2 López de Rioja, Víctor
Coma, Ermengol
Hermosilla Pérez, Eduardo
Fina, Francesc
Martínez Marcos, Montserrat
Mendioroz, Jacobo
Cabezas, Carmen
Montañola-Sales, Cristina
Prats, Clara
Soriano-Arandes, Antoni
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Ramon Llull. IQS
dc.subject.none.fl_str_mv Nirsevimab
RSV
Respiratory syncytial virus
Bronchiolitis
Epidemiology
Infants
Bronquitis en els infants
616.2
topic Nirsevimab
RSV
Respiratory syncytial virus
Bronchiolitis
Epidemiology
Infants
Bronquitis en els infants
616.2
description Respiratory syncytial virus (RSV) causes most of the cases of bronchiolitis and thousands of deaths annually, particularly in infants less than 6 months old. In Catalonia (Spain), infants born between April 2023 and March 2024 aged 0–6 months during their first RSV season have been candidates to receive nirsevimab, the novel monoclonal antibody against RSV, since October 2023. We aimed to analyse the dynamics of all-causes bronchiolitis diagnoses and RSV community infections in the current season and compare them to pre-nirsevimab epidemics. We collected epidemiological data from the Information System for Surveillance of Infections in Catalonia (SIVIC) on daily all-causes bronchiolitis clinical diagnoses and RSV-confirmed cases provided by rapid antigen tests in primary care practices. We calculated the rate ratio (RR) for the incidence of all-causes bronchiolitis for children aged 0-11 m-old with respect to 12-35 m-old between September 2014 and January 2024. We analysed the RR of the incidence of RSV-confirmed infection for 0-11 m-old and 12-35 m-old with respect to the > 35 m-old, from January 2021 to January 2024. We then computed the relative difference of the RR, designated as percentage of reduction of risk, between season 2023/2024 and former epidemics. With a global coverage recorded rate for nirsevimab of 82.2% in January 2024, the age-specific 0-11 m-old RR (95% CI) of RSV infection incidence for > 35 m-old was 1.7 (1.5–2.0) in season 2023/2024. The RR (95% CI) had been 7.4 (5.6–9.9), 8.8 (6.9–11.3), and 7.1 (5.7–8.9) in 2020/2021, 2021/2022, and 2022/2023, respectively. Regarding the incidence of all-causes bronchiolitis for the 0-11 m-old group compared to the 12-35 m-old, the pre-pandemic (2014/2015–2019/2020) and 2022/2023 RR (95% CI) were 9.4 (9.2–9.6) and 6.0 (5.7–6.2), respectively, significantly higher than the RR of 3.6 (3.4–3.8) for the most recent season, 2023/2024. Conclusion: Concurring with the introduction of nirsevimab, the risk of RSV infection for infants aged 0-11 m-old compared to > 35 m-old has been reduced by 75.6% (73.4–77.5) in last season, and the risk for all-causes bronchiolitis for 12-35 m-old by 61.9% (60.9–62.9) from the pre-pandemic period and by 39.8% (39.3–40.2) from the 2022/2023 epidemic, despite high RSV community transmission, especially in older infants.
publishDate 2024
dc.date.none.fl_str_mv 2024
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.14342/4730
https://doi.org/10.1007/s00431-024-05779-x
url http://hdl.handle.net/20.500.14342/4730
https://doi.org/10.1007/s00431-024-05779-x
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv European Journal of Pediatrics. 2024;183:5181–5189
info:eu-repo/grantAgreement/Fundació La Marató TV3/202134–30-31/
info:eu-repo/grantAgreement/AEI-MCIN/PN I+D/PDI2022-139215NB-I00
dc.rights.none.fl_str_mv © L'autor/a
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv © L'autor/a
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9 p.
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:DAU Arxiu Digital de la Universitat Ramon Llull
instname:Universitat Ramon Llull (URL)
instname_str Universitat Ramon Llull (URL)
reponame_str DAU Arxiu Digital de la Universitat Ramon Llull
collection DAU Arxiu Digital de la Universitat Ramon Llull
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418084900536320
score 15,81155

Similares en LA Referencia